Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg/m\^2, between the ages of 60 and 85 years that have mild functional impairment.

NCT Number	NCT07754045
Lead Sponsor	Lumos Pharma
Conditions	Obesity & Overweight
Enrollment	202 participants
Start Date	2027-02-15
Primary Completion	2028-02-15 (estimated)
Study Completion	2028-02-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-10